Proof of lost wages or decreased earning capacity due to health issues associated with Ozempic is necessary
This article distinguishes between what the brand states, what is verifiable through public documentation, and what requires direct buyer confirmation before enrolling
Analysts predict continued double-digit growth for the GLP-1/metabolic disease market, driven by global obesity trends and more indications
Pharmaceutical analysts agree this market will keep growing rapidly for at least the next decade
[DOI] [PMC free article] [PubMed] [Google Scholar] 76.Dore DD, Seeger JD, Arnold Chan K
Novo Nordisk, a competitor to Eli Lilly, has already sought FDA approval for an oral semaglutide pill, its oral GLP-1 pill, and is expected to receive a decision by the end of this year